Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir
Table 2
Antenatal antiretroviral exposure of infants.
Drug
Number exposed (%)
Nucleoside reverse transcriptase inhibitors
Abacavir
7 (4%)
Emtricitabine
15 (9.5%)
Lamivudine
126 (80%)
Stavudine
21 (13%)
Tenofovir
15 (9.5%)
Zidovudine
99 (63%)
Nonnucleoside reverse transcriptase inhibitors
Nevirapine
10 (6%)
Protease inhibitors
Atazanavir ± ritonavir
16 (10%)
Lopinavir + ritonavir
59 (37%)
Nelfinavir
41 (26%)
Saquinavir ± ritonavir
7 (4%)
Maternal treatment administered for ≥28 days of the 35 days immediately preceding delivery. Thirteen of sixteen women received ritonavir-boosted atazanavir.